Investigates how alternative RNA splicing contributes to cancer with the goal of identifying novel clinical biomarkers and targets for precision medicine.
My research goal is to elucidate how changes in gene expression regulation contribute to cancer. My lab focuses on characterizing the role of alternative-splicing misregulation in breast and ovarian cancer by using 3D cell culture and PDX models. Our unique expertise in both RNA biology and cancer research allows us to connect these distinct fields, and by combining innovative tools and interdisciplinary approaches, to gain novel insights into the molecular mechanism of gene expression regulation in normal and cancer cells. My research findings should lead to the development of novel biomarkers and promising drugs for cancer therapy.
See a recent article "Splicing factor to blame in triple negative breast cancer" on UCONN Today.